Anixa Biosciences (ANIX) Projected to Post Quarterly Earnings on Tuesday

Anixa Biosciences (NASDAQ:ANIX - Get Free Report) is projected to issue its Q2 2025 quarterly earnings data before the market opens on Tuesday, June 3rd. Analysts expect the company to announce earnings of ($0.10) per share for the quarter.

Anixa Biosciences (NASDAQ:ANIX - Get Free Report) last released its quarterly earnings results on Tuesday, June 3rd. The company reported ($0.09) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.10) by $0.01.

Anixa Biosciences Stock Up 1.6%

Shares of ANIX stock traded up $0.04 during trading hours on Wednesday, hitting $2.54. 23,656 shares of the company's stock traded hands, compared to its average volume of 89,483. The stock's 50 day simple moving average is $2.70 and its 200 day simple moving average is $2.81. The stock has a market cap of $81.78 million, a PE ratio of -6.51 and a beta of 0.43. Anixa Biosciences has a 12 month low of $2.07 and a 12 month high of $4.20.

Analysts Set New Price Targets

Several brokerages recently issued reports on ANIX. Maxim Group began coverage on Anixa Biosciences in a research report on Friday, March 21st. They set a "buy" rating and a $10.00 target price for the company. D. Boral Capital restated a "buy" rating and set a $10.00 price objective on shares of Anixa Biosciences in a research report on Thursday, April 10th. Finally, HC Wainwright restated a "buy" rating and set a $7.00 price objective on shares of Anixa Biosciences in a research report on Tuesday, March 25th.

About Anixa Biosciences

Anixa Biosciences, Inc, a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer.